Review Article
Genomic and Histopathological Tissue Biomarkers That Predict Radiotherapy Response in Localised Prostate Cancer
Table 2
Predictive tissue biomarkers for radiotherapy response identified using genomic techniques.
| Marker/signature | Function | Technique |
| DNA ploidy [52] | Genomic instability | Image analysis (Feulgen) and DNA/protein flow cytometry | Nuclear DNA content [53] | Genomic instability | Static DNA cytometry |
| c-myc [54] | Cell proliferation | Array CGH validated by FISH |
| PTEN [54] | Cell survival | Array CGH validated by FISH |
| E-cadherin [15] | Cell adhesion | PCR array, IHC validation |
| NKX3.1 [55] | Androgen related homeobox gene, DNA repair | Array CGH | NBN [56] | DNA damage response | Array CGH |
| StAR [57] | Androgen synthesis | Array CGH | HSD17B2 [57] | Androgen synthesis | Array CGH |
| Cell cycle progression score [58] | Cell cycle progression | RT-PCR (RNA expression) |
| CAN_RF [59] | Genomic and microenvironment heterogeneity | Array CGH, intraglandular hypoxia with piezoelectrode |
|
|
FISH: fluorescent in situ hybridisation; CGH: comparative genomic hybridisation; RT-PCR: reverse transcription polymerase chain reaction.
|